Clinical trial · Interventional
Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.
To Compare the Survival Differences in Patients With HCC and Portal Vein Tumor Thrombosis Treated With Liver Resection-based Therapy Versus Locoregional-based Therapy: a Prospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hepatocellular carcinoma is prone to invade the portal vein and form portal vein thrombosis, and patients in this period are directly included in the advanced stages, i.e. Barcelona clinical liver cancer stage C. For the treatment of PVTT, there are differences between Eastern and Western guidelines, with systemic drugs being the standard of care in Western countries, while surgical treatment is often actively practiced in the Asia-Pacific region. More research is needed to explore the differences between these two approaches.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Liver resection | Procedure | — | UNRESOLVED |
| Locoregional therapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Liver resection-based group
- description
- Patients in the liver resection-based group received adjuvant PD-1 inhibitors plus targeted drugs following liver resection.
- interventionNames
- Procedure: Liver resection
- type
- ACTIVE_COMPARATOR
- label
- Locoregional treatment-based group
- description
- Patients in the locoregional treatment-based group received PD-1 inhibitors plus targeted drugs following locoregional therapy.
- interventionNames
- Procedure: Locoregional therapy
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18-75 years * Pathological type is HCC, and with PVTT * No extrahepatic HCC * Eastern Cooperative Oncology Group (ECOG) performing status of 0-1 and Child-Pugh grade A for the liver resection group * ECOG performing status of 0-2 and Child-Pugh grade A-B for the locoregional-based group * Adequate hematologic and organ function Exclusion Criteria: * Any history of other malignant tumors or recurrent HCC * Any acute active infectious diseases, active or history of autoimmune disease, or immune deficiency * Any persistent serious liver resection or locoregional therapy-related complications * Esophageal and/or gastric variceal bleeding within 6 months * Inability or refusal to comply with the treatment and monitoring * Participation in other clinical trials
References
Publications (0)
Data not yet available